Protective action of EGCG against anticancer drugs MMS and CP

Abstract

This experiment was conducted in order to assess the antigenotoxicity potential of Epigallocatechin-3-gallate (EGCG), a catechin, against genotoxicity induced by anticancer drugs, Methyl methanesulphonate (MMS) and cyclophosphamide (CP), in the form of chromosomal aberrations (CAs) and sister chromatid exchanges (SCEs). These drugs were used at 60 M and 0.16 g/ml respectively along with EGCG at 10, 20, and 30 M in cultured human lymphocyte chromosomes. EGCG significantly reduced the genotoxic damage induced by the two drugs both in the presence and absence of metabolic activation system (S9 mix), although with greater effectiveness in the presence of metabolic activation.